A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects with Recently Diagnosed COVID-19 Compared to Standard of Care Treatment (BLADE)

Administered By

Awarded By

Contributors

Start/End

  • July 6, 2020 - July 31, 2022